T. Shimazaki

发表

Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection.

N. Sakamoto, K. Morikawa, T. Izumi, 2016, Annals of translational medicine.

Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma

N. Sakamoto, M. Natsuizaka, T. Sho, 2020, JGH open : an open access journal of gastroenterology and hepatology.

Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting

A. Saga, T. Miyagishima, T. Kamiyama, 2019, JGH open : an open access journal of gastroenterology and hepatology.

The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease

T. Sugiyama, N. Sakamoto, S. Ohnishi, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Analysis of the optimal psoas muscle mass index cut‐off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people

I. Yokota, T. Shimamura, M. Uebayashi, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease

N. Sakamoto, M. Natsuizaka, T. Sho, 2020 .

Reactivation of epstein–barr virus in B cells of patients with chronic hepatitis C

Takayoshi Ito, M. Imawari, K. Hiroishi, 2010, Journal of medical virology.

High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C

N. Sakamoto, M. Natsuizaka, M. Nishida, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis

N. Sakamoto, S. Ohnishi, M. Natsuizaka, 2018, Hepatology communications.

Anti‐adipogenic and antiviral effects of l‐carnitine on hepatitis C virus infection

F. Sato, N. Sakamoto, S. Ohnishi, 2017, Journal of medical virology.

Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma

Toshiyuki Baba, Takayoshi Ito, M. Sakaki, 2010, Journal of Gastroenterology.

Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients

M. Sugiyama, M. Mizokami, N. Sakamoto, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter

N. Sakamoto, M. Natsuizaka, Masaru Baba, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Entecavir treatment of hepatitis B virus‐infected patients with severe renal impairment and those on hemodialysis

N. Sakamoto, M. Natsuizaka, Masaru Baba, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Effects of resistance‐associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs

N. Sakamoto, M. Natsuizaka, T. Sho, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region.

K. Kaneko, R. Makino, K. Mitamura, 2002, Mutation research.

Fibroblast growth factor-2–mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma

H. Nakagawa, F. Sato, N. Sakamoto, 2017, Carcinogenesis.

Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C

Takayoshi Ito, Y. Miyakawa, K. Morikawa, 2009, Journal of medical virology.

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment

N. Sakamoto, M. Natsuizaka, Masaru Baba, 2018, Internal medicine.

Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases

N. Sakamoto, M. Natsuizaka, Masaru Baba, 2018, Internal medicine.

Magnitude of CD8+ T‐cell responses against hepatitis C virus and severity of hepatitis do not necessarily determine outcomes in acute hepatitis C virus infection

Takayoshi Ito, M. Sakaki, K. Morikawa, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence

N. Sakamoto, K. Morikawa, T. Shimazaki, 2018, Drug design, development and therapy.

Lymphotropic hepatitis C virus has an interferon‐resistant phenotype

K. Morikawa, T. Ito, M. Imawari, 2012, Journal of viral hepatitis.